Form 8-K PTC THERAPEUTICS, INC. For: Feb 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
PTC Therapeutics (PTCT) Posts Q4 Loss of 84c/Share
February 27, 2015 9:33 AM ESTPTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($0.84), $0.02 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $7.99 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
... More